Group 1 - The core viewpoint of the article highlights that Shengnuo Bio achieved significant growth in its financial performance for the first half of 2025, with a revenue of 338 million yuan, representing a year-on-year increase of 69.69% [1] - The net profit attributable to the company reached 88.96 million yuan, showing a remarkable year-on-year growth of 308.29% [1] - The increase in profits is attributed to a substantial rise in overseas sales of Semaglutide and Teriparatide raw materials during the reporting period [1]